Unternehmensübersicht
HCA Healthcare, Inc. operates as a comprehensive provider of health care services throughout the United States, owning and managing a diverse portfolio that includes hospitals, ambulatory surgery centers (ASCs), freestanding emergency care facilities, urgent care locations, walk-in clinics, as well as diagnostic and imaging centers and radiation and oncology therapy units. The company functions within the Healthcare sector, specifically in the Medical Care Facilities industry, positioning it as a central entity in the delivery of essential medical infrastructure and clinical services. With a market capitalization of $105.52B and annual revenue of $75.60B, HCA commands a substantial footprint in the American health care system. The organization employs approximately 230,000 individuals, reflecting its status as a large-scale enterprise with significant operational reach. These valuation and revenue figures indicate that the company is a major market participant with the capacity to influence health care pricing and availability across multiple states. The sheer scale of its operations, supported by a workforce of over two hundred and thirty thousand employees, underscores the critical role HCA plays in the national health care delivery network.
Finanzielle Gesundheit
HCA Healthcare reported total revenue of $75.60B over the trailing twelve months, generating net income of $6.78B and an EBITDA of $15.49B. The substantial difference between the gross revenue of $75.60B and the net income of $6.78B reveals a cost structure where operating expenses, including cost of goods sold, salaries, and administrative overhead, absorb a significant portion of top-line growth before reaching the bottom line. The company generated free cash flow of $5.82B, which provides a robust buffer for financial flexibility, allowing management to fund capital expenditures, service acquisitions, or repay debt obligations without relying heavily on external financing. Profitability analysis shows a gross margin of 41.5%, an operating margin of 16.3%, and a profit margin of 9.0%, indicating that while the company retains a healthy portion of revenue after direct costs, significant operational leverage is required to convert sales into operating profit. Regarding liquidity and leverage, the company holds $1.14B in cash against $48.70B in total debt, resulting in a debt-to-equity ratio that is listed as N/A in the available data, suggesting a capital structure heavily reliant on equity or where equity is not the primary denominator for this specific metric in the reported context. The current ratio stands at 0.96, which indicates that the company's current assets are slightly below its current liabilities, pointing to a balance sheet that requires careful management of short-term liquidity to meet upcoming obligations. Return on assets is reported at 12.4%, demonstrating that the company generates a solid return on its asset base, while return on equity is listed as N/A, preventing a direct assessment of how efficiently shareholder capital is being deployed relative to book value.
Bewertungsanalyse
The stock carries a trailing P/E ratio of 16.67 compared to a forward P/E of 14.18, implying that the market expects earnings growth in the future that would justify a lower valuation multiple than the historical average. The price-to-book ratio is listed as -17.58, a negative figure that indicates the market value of the company's equity does not align with its book value in a traditional sense, often seen in asset-heavy industries where book values may not reflect the true economic worth of the enterprise or where accumulated retained earnings differ significantly from market capitalization. Alternative valuation metrics such as the price-to-sales ratio of 1.40 and an EV/EBITDA of 10.09 provide different perspectives on value, suggesting that the company trades at a premium relative to its sales but offers a reasonable multiple of earnings before interest, taxes, depreciation, and amortization relative to enterprise value. The 52-week high for the stock is $556.52 and the 52-week low is $314.43, and without the specific current share price in the provided facts, the precise percentage distance from the high or low cannot be calculated, but the range demonstrates significant price volatility over the last year. The beta value of 1.34 indicates that the stock is more volatile than the broader market, meaning it tends to amplify market movements with greater swings in price.
Growth & Income
HCA Healthcare has achieved a revenue growth rate of 6.7% year-over-year and an earnings growth rate of 44.5% year-over-year, showing that earnings are expanding at a pace significantly faster than revenue. This divergence implies that the company is improving its operational efficiency or leveraging its scale to increase profitability per dollar of revenue sold. The company offers a dividend yield of 0.7% with a payout ratio of 10.2%, indicating that only a small fraction of earnings is distributed to shareholders. Given the low payout ratio of 10.2%, the company retains the vast majority of its earnings, providing a sustainable dividend while maintaining ample capital for reinvestment into its extensive hospital network and operational improvements. The overall growth and income profile suggests a mature asset-lightening strategy where the company prioritizes earnings expansion and balance sheet strength over high dividend payouts, balancing modest income returns with aggressive profitability growth.